From Yahoo Finance: 2025-05-17 17:28:00

Eli Lilly and Company (NYSE:LLY) partners with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments over $1.3 billion. Rznomics leads early research, while Lilly handles clinical development and commercialization with RNA editing technology. The collaboration complements Lilly’s existing genetic hearing loss pipeline, which includes AK-OTOF gene therapy. Industry focus on genetic hearing loss treatments is growing, with Regeneron’s DB-OTO showing positive results. Rznomics, which raised $58 million, sees the partnership as a step towards global expansion in biotech. CEO Seong-Wook Lee highlights the potential of precision RNA therapeutics for treating diseases.



Read more at Yahoo Finance: Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership